125742 S1 M5 5351 bnt162 01 interim3 investigators

Pfizer Documents (PHMPT/FDA)

Pfizer Bla Submission

Pfizer 16 Plus Documents

13

Document text

BioNTech RNA 
Pharmaceuticals GmbH  
Confidential  Interim Clinical Study  Report  
BNT162 -01 Page 1 of 1 
Version: NA 
Date: 02 Sep 2020  
 
16.1.4.1  List of investigators  
 
Site number  Investigator  Site type  Site address  Site status  Deputy investigator (s) at the site  
276-01 (Coordinating investigato r & 
Principal investigator  
Mannheim)  
Dr. Dr. med. Armin Schultz  Clinical CRO 
site CRS  Clinical Research Services 
Mann heim GmbH  
Grenadier Str.  1  
68167 Mannheim  
Germany  
 Open  Dr. med. Friedeborg Seitz  
276-02 (Principal investigator  Berlin)  
Dr. med. Sybille Baumann  Clinical CRO 
site CRS Clinical Research Services 
Berlin GmbH  
Seller  Str. 31  
13353 Berlin  
Germany  
 Open  Dr. med. Matthias Berse,  
Manuela Casjens MD  
CRO = contract research organization.  
 
090177e194f36bf2\Approved\Approved On: 18-Sep-2020 07:17 (GMT) 
Page 1
FDA-CBER-2021-5683-0049318
090177e194f36bec\Approved\Approved On: 18-Sep-2020 07:17 (GMT) 
  
 
     
 
  
 
  
  
 
 
 
  
  
  
       
  
     
 
 
      
  
  
 
   
   
  
    
    
 
     
  
  
  
   
 
  
  
   
 
        
   
   
 
     
    
Page 2
(b) (6)
(b) (6)
FDA-CBER-2021-5683-0049319
090177e194f36bec\Approved\Approved On: 18-Sep-2020 07:17 (GMT) 
 
  
  
  
  
  
  
  
  
   
   
     
     
 
      
 
      
 
     
     
 
 
     
     
      
 
        
      
   
     
     
    
       
      
 
  
  
  
 
  
     
      
 
   
   
      
 
      
    
    
Page 3
FDA-CBER-2021-5683-0049320
090177e194f36bec\Approved\Approved On: 18-Sep-2020 07:17 (GMT) 
   
        
  
   
      
 
   
      
       
 
    
Page 4
FDA-CBER-2021-5683-0049321
090177e194f36bed\Approved\Approved On: 18-Sep-2020 07:17 (GMT) 
  
 
     
 
  
 
  
 
  
 
  
  
        
  
     
  
 
      
    
     
   
 
    
       
 
  
   
    
 
 
   
    
 
 
   
  
 
   
   
   
 
 
   
    
 
    
Page 5
(b) (6)
(b) (6)
FDA-CBER-2021-5683-0049322
090177e194f36bed\Approved\Approved On: 18-Sep-2020 07:17 (GMT) 
  
  
   
 
   
  
       
        
      
     
   
   
      
 
   
      
 
 
   
Page 6
FDA-CBER-2021-5683-0049323
090177e194f36bee\Approved\Approved On: 18-Sep-2020 07:17 (GMT) 
  
 
     
 
  
 
 
  
  
  
  
 
  
        
  
   
 
 
      
 
   
 
     
  
 
 
    
  
 
    
  
 
 
  
  
 
    
       
 
  
   
 
     
  
 
    
Page 7
(b) (6)
(b) (6)
FDA-CBER-2021-5683-0049324
090177e194f36bee\Approved\Approved On: 18-Sep-2020 07:17 (GMT) 
  
  
  
  
   
  
        
            
 
   
    
 
        
      
    
   
    
 
    
   
      
 
  
   
      
 
   
      
    
   
  
 
   
Page 8
FDA-CBER-2021-5683-0049325
090177e194f36bef\Approved\Approved On: 18-Sep-2020 07:17 (GMT) 
  
 
     
 
  
 
  
  
  
  
 
  
  
        
  
     
 
 
      
   
     
  
     
     
 
    
     
     
 
  
    
    
 
    
     
   
   
 
  
   
 
      
     
   
   
Page 9
(b) (6)
(b) (6)
FDA-CBER-2021-5683-0049326
090177e194f36bef\Approved\Approved On: 18-Sep-2020 07:17 (GMT) 
     
     
          
       
  
  
 
  
  
  
     
      
       
 
  
      
       
 
    
       
 
    
      
    
 
     
      
 
   
   
      
 
  
   
      
 
               
  
      
 
   
Page 10
FDA-CBER-2021-5683-0049327
090177e194f36bf0\Approved\Approved On: 18-Sep-2020 07:17 (GMT) 
  
 
     
 
  
 
  
  
 
 
 
  
  
     
  
      
 
 
      
    
  
   
 
  
   
 
  
       
    
 
 
    
    
  
       
     
  
   
Page 11
(b) (6)
(b) (6)
FDA-CBER-2021-5683-0049328
090177e194f36bf0\Approved\Approved On: 18-Sep-2020 07:17 (GMT) 
  
  
  
  
    
   
  
 
  
      
       
    
     
      
 
 
   
      
 
        
      
   
      
        
 
   
Page 12
FDA-CBER-2021-5683-0049329
BioNTech RNA 
Pharmaceuticals GmbH  
Confidential  Interim Clinical Study  Report  
BNT162 -01 Page 1 of 1 
Version: 2.0 
Date: 26 Nov 2020  
 
16.1.4.3  List of providers  
 
Services provided  Name and address (including country)  
Medical monitoring  Bexon  Cinical Consulting, LLC, P.O. Box 3143,  
Memorial Station, Upper Montclair, NJ 07043, USA  
Trial conduct  CRS Clinical Research Services Andernach GmbH  
Rennweg 72, 56626 Andernach, Germany (no site, only main office)  
Clinical Monitoring  Origio Clinical Monitoring GmbH  
An den Deichwiesen 21a, Hannover, 30659 Germany  
Central laboratory analyses  MLM Medical Labs GmbH  
Dohrweg 63, D -41066 Moenchengladbach, Germany  
Statistics  Staburo GmbH, Aschauer Str. 26b, 81549 München, Germany  
Pharmacovigilance consultancy activities  SCRATCH Pharmacovigilance GmbH & Co. KG  
Schlossstrasse 25,  D-35510 Butzbach, Germany  
PV consultant activities  PHARMSOFT Dr. B. Rodust GmbH  
Königswall 22, 44137 Dortmund, Germany  
Sample processing  Precision for Medicine / Epiontis GmbH  
Barbara -McClintock - Str. 6, 12489 Berlin, Germany  
Specialty analysis  VisMederi , Strada del Petriccio e Belriguardo, 35 , 53100 Siena, Italy  
Specialty analysis  Pfizer Vaccine Research & Development  
401 North Middletown Road, Pearl River, NY 10965, USA  
Specialty analysis  Regeneron Pharmaceuticals  
777 Old Saw Mill River Rd, Ta rrytown, NY 10591, USA  
Sample processing  BioNTech RNA Pharmaceuticals GmbH,  
An der Goldgrube 12, 55131 Mainz, Germany  
Specialty analysis  BioNTech SE,  
An der Goldgrube 12, 55131 Mainz, Germany  
 
090177e195a37561\Approved\Approved On: 28-Nov-2020 02:37 (GMT) 
Page 13
FDA-CBER-2021-5683-0049330